|
| 37400643 | Author Correction: Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. | Nat Med | 2024 |
| 37591790 | pH-Weighted amine chemical exchange saturation transfer echo planar imaging visualizes infiltrating glioblastoma cells. | Neuro Oncol | 2024 |
| 37882836 | Simultaneous quantification of perfusion, permeability, and leakage effects in brain gliomas using dynamic spin-and-gradient-echo echoplanar imaging MRI. | Eur Radiol | 2024 |
| 37400643 | Author Correction: Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. | Nat Med | 2024 |
| 37591790 | pH-Weighted amine chemical exchange saturation transfer echo planar imaging visualizes infiltrating glioblastoma cells. | Neuro Oncol | 2024 |
| 37882836 | Simultaneous quantification of perfusion, permeability, and leakage effects in brain gliomas using dynamic spin-and-gradient-echo echoplanar imaging MRI. | Eur Radiol | 2024 |
| 36239925 | Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. | Neuro Oncol | 2023 |
| 36239925 | Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. | Neuro Oncol | 2023 |
| 35704275 | Amine-weighted chemical exchange saturation transfer magnetic resonance imaging in brain tumors. | NMR Biomed | 2023 |
| 35419607 | Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. | Neuro Oncol | 2023 |
| 36416495 | Corrigendum to: EGFR, the Lazarus target for precision oncology in glioblastoma. | Neuro Oncol | 2023 |
| 35853075 | Synthesizing MR Image Contrast Enhancement Using 3D High-Resolution ConvNets. | IEEE Trans Biomed Eng | 2023 |
| 37935104 | Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma. | J Clin Oncol | 2023 |
| 37655659 | Immune checkpoint blockade induces distinct alterations in the microenvironments of primary and metastatic brain tumors. | J Clin Invest | 2023 |
| 37584601 | Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways. | Cancer Discov | 2023 |
| 37573572 | Spatial immune profiling of glioblastoma identifies an inflammatory, perivascular phenotype associated with longer survival. | Acta Neuropathol | 2023 |
| 37790490 | Dendritic Cell Vaccination in Conjunction with a TLR Agonist Polarizes Interferon Immune Responses in Malignant Glioma Patients. | Res Sq | 2023 |
| 37554221 | Change in volumetric tumor growth rate after cytotoxic therapy is predictive of overall survival in recurrent glioblastoma. | Neurooncol Adv | 2023 |
| 37774317 | RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. | J Clin Oncol | 2023 |
| 37152809 | A single-institution retrospective analysis of pathologically determined malignant transformation in IDH mutant glioma patients. | Neurooncol Adv | 2023 |
| 36831380 | Multi-Parametric Radiomic Model to Predict 1p/19q Co-Deletion in Patients with IDH-1 Mutant Glioma: Added Value to the T2-FLAIR Mismatch Sign. | Cancers (Basel) | 2023 |
| 37402043 | The Future Glioblastoma Clinical Trials Landscape: Early Phase 0, Window of Opportunity, and Adaptive Phase I-III Studies. | Curr Oncol Rep | 2023 |
| 37027809 | Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent Glioblastoma. | J Clin Oncol | 2023 |
| 36581779 | ABTC-0904: targeting glioma stem cells in GBM: a phase 0/II study of hedgehog pathway inhibitor GDC-0449. | J Neurooncol | 2023 |
| 37272516 | Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. | N Engl J Med | 2023 |
| 36823302 | Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. | Nat Med | 2023 |
| 36702828 | Author Correction: Federated learning enables big data for rare cancer boundary detection. | Nat Commun | 2023 |
| 37128507 | Retrospective examination of pseudoprogression in IDH mutant gliomas. | Neurooncol Adv | 2023 |
| 37188783 | Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. | Nat Med | 2023 |
| 36939557 | Accessible Data Collections for Improved Decision Making in Neuro-Oncology Clinical Trials. | Clin Cancer Res | 2023 |
| 37436895 | SREBP-1 upregulates lipophagy to maintain cholesterol homeostasis in brain tumor cells. | Cell Rep | 2023 |
| 36617262 | Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival. | Neuro Oncol | 2023 |
| 37236196 | CDKN2A deletion remodels lipid metabolism to prime glioblastoma for ferroptosis. | Cancer Cell | 2023 |
| 37294422 | Multi-nuclear sodium, diffusion, and perfusion MRI in human gliomas. | J Neurooncol | 2023 |
| 37167013 | Reply to Di Nunno et al. concerning objective response rates targets for recurrent glioblastoma clinical trials: Toward surrogate endpoints for phase II trials in patients with recurrent glioblastoma. | Neuro Oncol | 2023 |
| 37540556 | Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma. | Clin Cancer Res | 2023 |
| 37488293 | Correcting the drug development paradigm for glioblastoma requires serial tissue sampling. | Nat Med | 2023 |
| 36843451 | Diagnosis and management of complications from the treatment of primary central nervous system tumors in adults. | Neuro Oncol | 2023 |
| 37488293 | Correcting the drug development paradigm for glioblastoma requires serial tissue sampling. | Nat Med | 2023 |
| 37554221 | Change in volumetric tumor growth rate after cytotoxic therapy is predictive of overall survival in recurrent glioblastoma. | Neurooncol Adv | 2023 |
| 37655659 | Immune checkpoint blockade induces distinct alterations in the microenvironments of primary and metastatic brain tumors. | J Clin Invest | 2023 |
| 37584601 | Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways. | Cancer Discov | 2023 |
| 37790490 | Dendritic Cell Vaccination in Conjunction with a TLR Agonist Polarizes Interferon Immune Responses in Malignant Glioma Patients. | Res Sq | 2023 |
| 37935104 | Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma. | J Clin Oncol | 2023 |
| 37540556 | Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma. | Clin Cancer Res | 2023 |
| 37774317 | RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. | J Clin Oncol | 2023 |
| 37573572 | Spatial immune profiling of glioblastoma identifies an inflammatory, perivascular phenotype associated with longer survival. | Acta Neuropathol | 2023 |
| 35704275 | Amine-weighted chemical exchange saturation transfer magnetic resonance imaging in brain tumors. | NMR Biomed | 2023 |
| 35853075 | Synthesizing MR Image Contrast Enhancement Using 3D High-Resolution ConvNets. | IEEE Trans Biomed Eng | 2023 |
| 35419607 | Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. | Neuro Oncol | 2023 |